Invion Announces Complete Dosing in Phase II Study of Inv102 in Smoking Cessation For COPD Patients
COPD, News
Invion Limited, an Australian clinical-stage drug development company focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus, recently announced the completion ... Read more